Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionTc99m-labeled murine antibody fragment for nuclear imaging of CD22-expressing lymphomas
Molecular Target CD22
Mechanism of ActionDiagnostic; Imaging agent
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationCancer, Diagnostic
Indication DetailsCancer, Diagnostic; Detect stages of non-Hodgkin's B cell lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today